Results 91 to 100 of about 144,925 (192)

Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region [PDF]

Middle East Journal of Cancer
Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC.
Shaheenah Dawood, Mohsen Mokhtar, Ahmed Alwbari, Bernardo Rapoport, Ece Esin, Hassan Jaafar, Jamal Zekri, Narjiss Berrada, Ozgur Ozyilkan, Nagi El Saghir   +9 more
doaj   +1 more source

Positive Chemotactic Flasklike Colloidal Motors Propelled by Rotary FoF1-ATP Synthases

Research
Living microorganisms can perform directed migration for foraging in response to a chemoattractant gradient. We report a biomimetic strategy that rotary FoF1-ATPase (adenosine triphosphatase)-propelled flasklike colloidal motors exhibit positive ...
Yue Li, Yingjie Wu, Qiang He
doaj   +1 more source

Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer With BRCA Gene Mutations: A Narrative Review. [PDF]

Cureus, 2023
Jain P.
europepmc   +1 more source

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, Volume 209, Issue 3, Page 1350-1353, September 2026.
Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya, Julia Alesse, Noel English, Lizzie Sheehan, Nikita Syzrantsev, Alexander Nesmelov, Hans‐Guido Wendel, Paolo Strati   +10 more
wiley   +1 more source

Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells

Tumor Biology, 2017
Cell adhesion–mediated drug resistance is an important factor that influences the effects of chemotherapy in multiple myeloma. DTX3L, a ubiquitin ligase, plays a key role in cell-cycle-related process.
Yaodong Shen, Yuxiang Sun, Linlin Zhang, Hong Liu   +3 more
doaj   +1 more source

Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma. [PDF]

Cureus, 2022
Magalhães D, Bartosch C, Abreu MH.
europepmc   +1 more source

Programmed death ligand 1, poly adenosine diphosphate ribose polymerase, and vascular endothelial growth factor receptor inhibition: a potential combination regimen for targeting triple-negative breast cancer? [PDF]

Int J Surg, 2023
Abdul Wahid M, Hussain HU, Ghouri H, Khan T, Rehan ST, Mumtaz H.   +5 more
europepmc   +1 more source

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer. [PDF]

Cureus, 2022
Sunkara T, Bandaru SS, Boyilla R, Kunadharaju R, Kukkadapu P, Chennamadhavuni A.   +5 more
europepmc   +1 more source

Accumulation of poly (adenosine diphosphate-ribose) by sustained supply of calcium inducing mitochondrial stress in pancreatic cancer cells. [PDF]

World J Gastroenterol, 2022
Jeong KY, Sim JJ, Park M, Kim HM.
europepmc   +1 more source

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study

Cell Reports Medicine
Summary: Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.
Tingwei Zhang, Beihe Wang, Yu Wei, Hualei Gan, Bangwei Fang, Xiaomeng Li, Junlong Wu, Xiaojie Bian, Jianfei Wang, Stephen J. Freedland, Shenglin Huang, Dingwei Ye, Yao Zhu   +12 more
doaj   +1 more source